Assessment of the Efficacy of Spironolactone for COVID-19 ARDS Patients

Abstract

INTRODUCTION AND AIM The aim of our study is to compare patients monitored for ARDS diagnosis linked to COVID-19 treated with spironolactone with patients who did not use spironolactone and to retrospectively identify whether there was any positive effect on mortality using clinical and laboratory data from patients. MATERIAL AND METHOD Two groups were created of patients treated due to severe ARDS diagnosis linked to COVID-19. One group administered spironolactone (Group S, n=30) and the other group was not (Group F, n=30). Groups were compared in terms of demographic characteristics, presence of comorbidity, inotropic agent requirements, (intensive care unit) ICU length of stay’, days of mechanical ventilation and mortality. Additionally, fever, PO2/FIO2 (Horowitz ratio), lymphocyte count, CRP value, SOFA scorer, and d-dimer levels on the ICU length of stay, 1st day, 3rd day, 5th day, 8th day, 12th day, day of discharge or day of exitus were compared between the groups and statistically analyzed. RESULTS Group S was found to have a higher ICU length of stay and days of mechanical ventilation compared to Group F. (p<0.05). Group F had significantly a higher mortality rate compared to Group S. (p<0.05). The final Horowitz value in Group F was found to be significantly lower compared to Group S. (p<0.05). The lymphocyte values in Group F were significantly lower than Group S on the 1st, 3rd, 5th, 8th and 12th day and at the final measurement. (p<0.05). The CRP values in Group F were significantly higher than Group S on the 3rd, 5th, 8th and 12th day and at the final measurement. (p<0.05). The SOFA scores on the 8th and 12th days and at the final measurement in Group F were found to be significantly higher than GroupS. (p<0.05). CONCLUSION In our study, parameters for disease severity regressed, patients survived for longer and mortality was identified to be lower in the group using spironolactone